Understanding CD8(+) T-cell responses toward the native and alternate HLA-A*02:01-restricted WT1 epitope

Plebanski, M 2017, 'Understanding CD8(+) T-cell responses toward the native and alternate HLA-A*02:01-restricted WT1 epitope', Clinical and Translational Immunology, vol. 6, no. 3, pp. 1-1.


Document type: Journal Article
Collection: Journal Articles

Title Understanding CD8(+) T-cell responses toward the native and alternate HLA-A*02:01-restricted WT1 epitope
Author(s) Plebanski, M
Year 2017
Journal name Clinical and Translational Immunology
Volume number 6
Issue number 3
Start page 1
End page 1
Total pages 1
Publisher John Wiley & Sons Ltd.
Abstract The Wilms' tumor 1 (WT1) antigen is expressed in solid and hematological malignancies, but not healthy tissues, making it a promising target for cancer immunotherapies. Immunodominant WT1 epitopes, the native HLA-A2/WT1(126-134) (RMFPNAPYL) (HLA-A2/RMFPNAPYL epitope (WT1A)) and its modified variant YMFPNAPYL (HLA-A2/YMFPNAPYL epitope (WT1B)), can induce WT1-specific CD8(+) T cells, although WT1B is more stably bound to HLA-A*02:01. Here, to further determine the benefits of those two targets, we assessed the naive precursor frequencies; immunogenicity and cross-reactivity of CD8(+) T cells directed toward these two WT1 epitopes. Ex vivo naive WT1A- and WT1B-specific CD8(+) T cells were detected in healthy HLA-A*02:01(+) individuals with comparable precursor frequencies (1 in 10(5)-10(6)) to other naive CD8(+) T-cell pools (for example, A2/HIV-Gag(77-85)), but as expected, similar to 100x lower than those found in memory populations (influenza, A2/M158-66; EBV, A2/BMLF1280-288). Importantly, only WT1A- specific naive precursors were detected in HLA-A2.1 mice. To further assess the immunogenicity and recruitment of CD8(+) T cells responding to WT1A and WT1B, we immunized HLA-A2.1 mice with either peptide. WT1A immunization elicited numerically higher CD8(+) T-cell responses to the native tumor epitope following re-stimulation, although both regimens produced functionally similar responses toward WT1A via cytokine analysis and CD107a expression. Interestingly, however, WT1B immunization generated cross-reactive CD8(+) T-cell responses to WT1A and could be further expanded by WT1A peptide revealing two distinct populations of single-and cross-reactive WT1A(+)CD8+ T cells with unique T-cell receptor-alpha beta gene signatures. Therefore, although both epitopes are immunogenic, the clinical benefits of WT1B vaccination remains debatable and perhaps both peptides may have separate clinical benefits as treatment targets.
Subject Immunology not elsewhere classified
DOI - identifier 10.1038/cti.2017.4
Copyright notice ©
ISSN 2050-0068
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 7 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Altmetric details:
Access Statistics: 14 Abstract Views  -  Detailed Statistics
Created: Thu, 06 Dec 2018, 10:39:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us